诚达药业
(301201)
| 流通市值：38.38亿 | | | 总市值：54.71亿 |
| 流通股本：1.09亿 | | | 总股本：1.55亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 255,491,382.8 | 128,239,954.61 | 406,371,974.56 | 285,094,723.46 |
| 营业收入 | 255,491,382.8 | 128,239,954.61 | 406,371,974.56 | 285,094,723.46 |
| 二、营业总成本 | 255,972,818.53 | 123,429,214.85 | 401,421,371.25 | 277,205,588.06 |
| 营业成本 | 176,578,812.47 | 85,751,126.01 | 226,873,287.92 | 155,688,002.3 |
| 税金及附加 | 2,116,294.5 | 316,846.57 | 5,289,987.24 | 2,713,924.54 |
| 销售费用 | 2,736,210.63 | 1,325,001.14 | 4,565,533.16 | 3,715,480.56 |
| 管理费用 | 48,200,742.24 | 23,102,880.63 | 123,535,343.21 | 84,705,788.46 |
| 研发费用 | 22,666,332.21 | 11,007,401.05 | 40,178,441.2 | 30,277,440.98 |
| 财务费用 | 3,674,426.48 | 1,925,959.45 | 978,778.52 | 104,951.22 |
| 其中:利息费用 | 775,523.32 | 398,900.5 | 2,281,414.88 | - |
| 其中:利息收入 | 427,449.91 | 180,531.62 | 1,515,214.67 | - |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 6,177,968.26 | 2,958,293.65 | 2,849,373.74 | 2,794,911.28 |
| 加:投资收益 | -1,005,813.44 | 30,838.79 | 12,343,763.11 | 10,034,592.63 |
| 资产处置收益 | -52,477.88 | 7,168.14 | 37,332.75 | 37,332.75 |
| 资产减值损失(新) | -1,108,434.47 | 3,267,979.87 | -34,930,579.67 | -4,579,287.31 |
| 信用减值损失(新) | -745,574.88 | -1,541,896.77 | -635,598.75 | -508,171.94 |
| 其他收益 | 476,891.41 | 278,348.23 | 7,554,349.89 | 3,381,271.39 |
| 四、营业利润 | 3,261,123.27 | 9,811,471.67 | -7,830,755.62 | 19,049,784.2 |
| 加:营业外收入 | 10,023.4 | 6,010.98 | 517,241.53 | 30,247.8 |
| 减:营业外支出 | 1,135,228.46 | 456,606.36 | 5,950,340.08 | 1,105,840.33 |
| 五、利润总额 | 2,135,918.21 | 9,360,876.29 | -13,263,854.17 | 17,974,191.67 |
| 减:所得税费用 | -156,692.07 | 2,339,091.5 | -1,302,631.96 | 1,181,139.62 |
| 六、净利润 | 2,292,610.28 | 7,021,784.79 | -11,961,222.21 | 16,793,052.05 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 2,292,610.28 | 7,021,784.79 | -11,961,222.21 | 16,793,052.05 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 2,299,706.82 | 7,001,953.35 | -11,925,796.02 | 16,773,326.2 |
| 少数股东损益 | -7,096.54 | 19,831.44 | -35,426.19 | 19,725.85 |
| 扣除非经常损益后的净利润 | -5,272,563.49 | 3,098,557.31 | -26,692,917.25 | 3,902,548.54 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.02 | 0.05 | -0.08 | 0.11 |
| (二)稀释每股收益 | 0.02 | 0.05 | -0.08 | 0.11 |
| 八、其他综合收益 | - | - | -6,298,500 | - |
| 归属于母公司股东的其他综合收益 | - | - | -6,298,500 | - |
| 九、综合收益总额 | 2,292,610.28 | 7,021,784.79 | -18,259,722.21 | 16,793,052.05 |
| 归属于母公司股东的综合收益总额 | 2,299,706.82 | 7,001,953.35 | -18,224,296.02 | 16,773,326.2 |
| 归属于少数股东的综合收益总额 | -7,096.54 | 19,831.44 | -35,426.19 | 19,725.85 |
| 公告日期 | 2026-08-26 | 2026-04-28 | 2026-04-28 | 2025-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |